From: Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy
SCC-Ag (n = 112)*
SCC-Ag (n = 77)†
Sensitivity
11/18 (61.1%)
11/16 (68.8%)
Specificity
92/94 (97.9%)
59/61 (96.7%)
PPV
11/13 (84.6%)
NPV
92/99 (92.9%)
59/64 (92.2%)